Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'
Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'
Eli Lilly And Co (NYSE:LLY) "could be on its way to becoming a $1 trillion market cap company," according to analysts at Cantor Fitzgerald.
坎託·菲茨傑拉德的分析師表示，禮來公司（紐約證券交易所代碼：LLY）“可能即將成爲一家市值1萬億美元的公司”。
The assessment comes on the heels of an earnings report that shows first-quarter revenue of $8.77 billion. That's up 26% year-over-year, just marginally missing the consensus of $8.92 billion.
該評估是在業績發佈之後進行的，該報告顯示第一季度收入爲87.7億美元。同比增長26％，略低於89.2億美元的共識。
The Indianapolis-based company saw increases of 16% in volume and 10% in higher realized prices.
這家總部位於印第安納波利斯的公司的銷量增長了16％，實現價格上漲了10％。
Eli Lilly posted an adjusted EPS of $2.58, beating the consensus of $2.46, higher than $1.62 a year ago. Here's how analysts reacted:
禮來公司公佈的調整後每股收益爲2.58美元，高於市場預期的2.46美元，高於去年同期的1.62美元。以下是分析師的反應：
- Cantor raised its price target from $815 to $885 with an Overweight rating, driven by earnings revisions.
- BofA reiterated the Buy rating with a price target of $1,000.
- Truist maintains the Buy rating with a price target increased from $850 to $892.
- 在收益調整的推動下，坎託將目標股價從815美元上調至885美元，增持評級。
- 美國銀行重申了買入評級，目標股價爲1,000美元。
- Truist維持買入評級，目標股價從850美元上調至892美元。
Cantor: Despite the top-line miss that was widely anticipated due to supply constraints, Eli Lilly's sales growth of 26% in Q1 2024 is still impressive, the analysts note. The industry average is mid-to-low single digits.
坎託：分析師指出，儘管由於供應限制，人們普遍預計收入會出現虧損，但禮來公司2024年第一季度26％的銷售增長仍然令人印象深刻。行業平均水平爲中到低的個位數。
BofA Securities: While earnings beat and forecast raise is expected throughout 2024, the magnitude this early in the year impressed investors, particularly given recent questions on Lilly's ability to manufacture enough supply for its incretin franchise.
美銀證券：儘管收益超過預期，預計將在2024年全年上漲，但今年年初的規模給投資者留下了深刻的印象，特別是考慮到最近有人質疑禮來是否有能力爲其incretin特許經營權制造足夠的供應。
With this backdrop, analysts highlight Lilly's unparalleled growth profile and underscoring it's a "have" in a sea of "have nots."
在這種背景下，分析師強調了禮來公司無與倫比的增長狀況，並強調它是 “窮人” 海洋中的 “擁有”。
Truist: The analyst notes that Mounjaro/Zepbound's strong performance drove solid first-quarter revenues, and underlying demand seems healthy.
Truist：分析師指出，Mounjaro/Zepbound的強勁表現推動了第一季度穩健的收入，潛在需求似乎很健康。
Truist sees progress made to address manufacturing constraints, which remain at the top of mind given that demand is expected to exceed supply throughout 2024.
Truist認爲，在解決製造業限制方面取得了進展，鑑於預計2024年全年需求將超過供應，這仍然是人們關注的重中之重。
Price Action: Eli Lilly shares are down 0.14% at $779.98 at the last check Wednesday.
價格走勢：禮來公司股價在週三的最後一次檢查中下跌0.14％，至779.98美元。